Skip to content

Columbia Ventures Corporation

Creating, Discovering and Enhancing Capital Values

  • Team
  • Philosophy
  • Portfolio
    • Augmented Reality
    • Biomedical
    • Energy
    • Food
    • Hospitality
    • Manufacturing
    • Real Estate Development
    • Robotics
    • Software as a Service
    • Telecommunications
    • Past Investments
  • News
  • Contact
Columbia Ventures Corporation

AbSci announces completion of $125 million crossover financing to advance AI-powered synthetic biology drug creation platform

Read now on prnewswire.com • March 23, 2021

Share this:

  • Share on X (Opens in new window) X
  • Share on Facebook (Opens in new window) Facebook
Like Loading...
Unknown's avatarAuthor Columbia VenturesPosted on March 23, 2021Categories AbSci, BIOMEDICAL

Post navigation

Previous Previous post: RealWear establishes customer experience centre in Dubai
Next Next post: Vancouver-based AbSci wins $125 million from new investors

Recent News

  • Iceland volcano erupts, but there’s no stopping Matorka December 21, 2023
  • Absci and Caltech collaborate to accelerate affordable HIV therapeutic vaccine August 17, 2023
  • Headset firm appoint co-founder as new CEO August 11, 2023
Copyright © Columbia Ventures Corporation. All Rights Reserved.

News by Industry/Company

Search Site

  • Team
  • Philosophy
  • Portfolio
    • Augmented Reality
    • Biomedical
    • Energy
    • Food
    • Hospitality
    • Manufacturing
    • Real Estate Development
    • Robotics
    • Software as a Service
    • Telecommunications
    • Past Investments
  • News
  • Contact
Columbia Ventures Corporation Create a website or blog at WordPress.com
  • Reblog
  • Subscribe Subscribed
    • Columbia Ventures Corporation
    • Already have a WordPress.com account? Log in now.
    • Columbia Ventures Corporation
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Copy shortlink
    • Report this content
    • View post in Reader
    • Manage subscriptions
    • Collapse this bar
%d